AI assistant
Sending…
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2022
Jun 16, 2022
33148_dirs_2022-06-15_7de5797a-9ac6-4320-b242-739cd6a53b32.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2022-06-13
Reporting Person: SOUTHWELL DAVID P (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-06-13 | Stock Option (Right to Buy) | $10.77 | A | 47745 | Acquired | 2032-06-13 | Common Stock (47745) | Direct |
Footnotes
F1: This option represents a right to purchase a total of 47,745 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 13, 2023.
More from ROCKET PHARMACEUTICALS, INC.
Merger & Acquisition
2026
May 28
Declaration of Voting Results & Voting Rights Announcements
2026
May 21
Capital/Financing Update
2026
Apr 28
Proxy Solicitation & Information Statement
2026
Apr 6
Major Shareholding Notification
2026
Mar 27
Regulatory Filings
2026
Mar 27
Capital/Financing Update
2026
Mar 2
Earnings Release
2026
Feb 26
Annual Report
2026
Feb 26
Director's Dealing
2026
Feb 20